DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Oncology Based In-vivo CRO Market Analysis By Indication (Blood cancer, Solid tumor), By Model (Syngeneic model, Patient Derived Xenograft (PDX), Xenograft), By Region, And Segment Forecasts, 2014 - 2025" report to their offering.
The global oncology based in-vivo CRO market is expected to reach USD 1.5 billion by 2025
The use of Contract Research Organization (CRO) oncology services helps the manufacturers/sponsors to provide complete attention on the production capacity and at enhancing their in-house processes.
Furthermore, the pressure from the increasing competition due to patent expirations, rapid growth of generics, and introduction of biosimilar equivalents are propelling the pharmaceutical companies to take the aid of such organizations. Hence, it can be predicted that the oncology based in-vivo CRO market may witness lucrative growth over the forecast period.
Another factor propelling growth is the increasing incidence of cancer, and high failure rate of existing treatment options. According to statistics published by the World Health Organization (WHO), approximately 8.2 million deaths are recorded each year from cancer, which accounts for 13.0% deaths worldwide.
Key Topics Covered:
1 Research Methodology
2 Executive Summary
3 Oncology in-vivo CRO Market Variables, Trends, & Scope
4 Oncology in-vivo CRO Market: Indication Estimates & Trend Analysis
5 Oncology in-vivo CRO Market: Regional Estimates & Trend Analysis, by Indication
6 Competitive Landscape
- Charles River Laboratory (CRL)
- ICON Plc
- Eurofins Scientific
- Taconic Biosciences
- Crown Bioscience
- Toxikon, Inc.
- WuXi AppTec
- The Jackson Laboratory
For more information about this report visit https://www.researchandmarkets.com/research/c9qd9g/oncology_based